This article was originally published in The Gray Sheet
Executive SummaryLetter of intent is signed under which urinary incontinence treatment firm Uroplasty will purchase Empi's Clinical EMG System for $400,000. The product is a biofeedback device used to treat UI. Closing of the deal is subject to certain conditions, including the negotiation and execution of a definitive agreement and Uroplasty's due diligence review of "certain software" related to the system, according to Minneapolis-based Uroplasty, which is developing the Macroplastique injectable treatment for female stress UI
You may also be interested in...
CMR Surgical CEO Martin Frost is making way for a new boss to lead the surgical robotics company. Per Vegard Nerseth is set to join CMR Surgical in January 2020 as the company gears up for its most ambitious year yet.
While the BCMA-targeting CAR-T competition is grabbing attention, bluebird has good news in sickle cell therapy.
AstraZeneca’s Lynparza can now be used on the Scottish National Health Service for newly diagnosed advanced ovarian cancer.